Scarica l'app Stockscreener
4.50
4.26%
-0.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Precedente Chiudi:
$4.70
Aprire:
$4.7
Volume 24 ore:
2.52M
Relative Volume:
1.99
Capitalizzazione di mercato:
$775.52M
Reddito:
$62.04M
Utile/perdita netta:
$-533.34M
Rapporto P/E:
-1.148
EPS:
-3.92
Flusso di cassa netto:
$-473.07M
1 W Prestazione:
-19.79%
1M Prestazione:
-19.21%
6M Prestazione:
-47.92%
1 anno Prestazione:
-55.36%
Intervallo 1D:
$4.35
$4.7201
Intervallo di 1 settimana:
$4.35
$5.57
Portata 52W:
$4.35
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Nome
Vir Biotechnology Inc
Settore
Industria
Telefono
415-906-4324
Indirizzo
1800 OWENS STREET, SAN FRANCISCO, CA
Confronta VIR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
4.50 | 775.52M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-03-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Iniziato | SVB Leerink | Outperform |
| 2022-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2022-03-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-01-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-09-14 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-11 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Iniziato | Needham | Buy |
| 2020-03-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-02-27 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Iniziato | Robert W. Baird | Neutral |
| 2019-11-05 | Iniziato | Barclays | Overweight |
| 2019-11-05 | Iniziato | Cowen | Outperform |
| 2019-11-05 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN
Vir announces 24-week post-end of treatment data for Hep B therapy - MSN
Vir Biotechnology (VIR) Maintains 'Buy' Rating as Price Target A - GuruFocus
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference - BioSpace
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st
Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance
Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - BioSpace
Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus
Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey
Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha
Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha
Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks
Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Advancements - GuruFocus
Vir Biotechnology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - BioSpace
Vir Biotechnology Q1 2025 Earnings Call Transcript - MarketBeat
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
Earnings call transcript: Vir Biotech Q1 2025 reports increased R&D expenses - Investing.com India
Vir Biotechnology (VIR) Falls Short on Q1 Revenue, Advances Clinical Programs | VIR Stock News - GuruFocus
Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 1c - StreetInsider
Vir Biotechnology Q1 2025 Earnings Preview - MSN
Earnings Outlook For Vir Biotechnology - Nasdaq
Vir Biotechnology Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView
(VIR) On The My Stocks Page - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Vir Biotechnology Inc. - GuruFocus
Will Vir Biotech's Hepatitis B And D Data Presentations Give The Stock A Much-Needed Boost? - RTTNews
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 - BioSpace
Vir Biotechnology SVP sells shares for $14,291 - MSN
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver Congress 2025 - marketscreener.com
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 - BioSpace
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | VIR Stock News - GuruFocus
When (VIR) Moves Investors should Listen - news.stocktradersdaily.com
5 Analysts Have This To Say About Vir Biotechnology - Benzinga
Lobbying Update: $50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed - Nasdaq
New Mpro inhibitors revealed in Vir Biotechnology patent - BioWorld MedTech
Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple - Insider Monkey
10 Stocks Under $10 that Will Triple - Insider Monkey
Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock By Investing.com - Investing.com South Africa
Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock - Investing.com
Vir Biotechnology CEO Sells Shares to Cover Tax Obligations - TradingView
Vir Biotechnology stock hits 52-week low at $6.07 By Investing.com - Investing.com Australia
Vir Biotechnology Inc Azioni (VIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):